Pre-market
Loading markets…

Advertisement

Stocks

Why Eupraxia Pharmaceuticals Inc stock surged yesterday

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:EPRX.TO

Follow EPRX

Photos provided by Pexels

Eupraxia Pharmaceuticals Inc experienced a notable surge in its stock price, closing up over 8% in yesterday's trading session.

Eupraxia Pharmaceuticals Inc (EPRX.TO) saw its stock climb by 8.06% yesterday, closing at CA$10.05. This uptick comes amid a backdrop of positive sentiment surrounding the company, particularly following recent financial disclosures and clinical trial updates.

Advertisement

Eupraxia Pharmaceuticals Inc

EPRX.TO

Full stock page →

EPRX.TO

Eupraxia Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↑ $0.31 (3.10%)
120 day period
$8.22$10.61$12.99Apr 14Jul 9Oct 2

Market cap

$681.88M

52W high

$13.08

52W low

$7.35

1W change

-11.42%

Beta

1.49

Analyst Price Targets

Based on analyst covering EPRX · as of Sep 28, 2026

📈

Wall Street analysts forecast EPRX stock price to rise 58.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$16.33

+58.3% Upside

Previously C$16.00 on Sep 17, 2026

Current Price

C$10.32

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EPRX's historical volatility

HistoricalForecast68%95%
C$3.47C$9.94C$16.40C$22.87C$29.33C$35.80TodayMay 27Jul 30Oct 2Nov 14Dec 28Feb 9

30-Day Vol

95.1%

Annualized

90-Day Vol

69.3%

Annualized

Trend (90d)

+21.7%

Annualized drift

90d Mean

C$11.15

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$10.59C$7.63 – C$14.70
60 trading daysC$10.87C$6.83 – C$17.29
90 trading daysC$11.15C$6.32 – C$19.69

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should monitor Eupraxia's ongoing clinical trials and financial health, as these factors could significantly influence future stock performance.

Eupraxia Pharmaceuticals Inc Market Cap Reaches CA$664 Million

The company’s market capitalization now stands at approximately CA$664 million, reflecting increased investor interest and confidence.

Bull case

The recent surge suggests that investors are growing more confident in Eupraxia's pipeline. Promising data from its EP-104GI trials and new executive appointments could improve the company’s operational efficiency and attract further investment.

Bear case

Despite the positive movement, it’s wise for investors to stay cautious. The lack of immediate news or catalysts after this surge might lead to fluctuations in the stock price.

Recent Performance Overview

Advertisement

Eupraxia Pharmaceuticals Inc's stock surged by 8.06% in yesterday's session, closing at CA$10.05. This performance reflects a growing optimism among investors, particularly in light of the company's recent financial results and the promising data emerging from its clinical trials.

Market Reaction and Future Outlook

The increase in Eupraxia's stock price signals a positive market reaction to its ongoing developments. Investors are keenly watching the outcomes of the EP-104GI trials, which could be pivotal for the company's future. Additionally, the recent strategic appointments within the company may enhance its operational capabilities, further boosting investor confidence.

Key Financial Metrics

Eupraxia Pharmaceuticals Inc currently holds a market cap of approximately CA$664 million. While the company does not have a P/E ratio or dividend yield to report, the recent stock performance indicates a strong interest in its growth potential, especially as it navigates through critical clinical phases.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 25, 2026
Last Updated: October 3, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement